Dustin Armstrong, PhD

Chief Scientific Officer, Valerion

Dr. Armstrong founded Valerion, formerly 4s3 Bioscience, in 2007 and as Chief Scientific Officer he has lead the company’s scientific efforts for program development; including, target identification, product generation, and feasibility studies. Dr. Armstrong manages development programs in the area of orphan genetic muscle disease as well as oncology applications and development of the Valerion… Read More »

Steve Gillies, PhD

Chief Scientfic Officer, Alopexx Oncology

Dr. Gillies is an expert in the creation and development of recombinant antibodies and immunotherapies. Currently he serves as both the CSO of Alopexx Oncology and as the Founder and CEO of Provenance Biopharmaceuticals corp. Prior to founding Provenance, Dr. Gillies led all scientific and business endeavors of Lexigen Pharmaceuticals Corp. After Lexigen’s acquisition in… Read More »

Hal Landy, MD

Chief Medical Officer, Valerion

Dr. Landy is a board certified Pediatric Endocrinologist with 30 years of clinical research experience in academics and industry, primarily in rare orphan diseases.  Educated at Harvard College (AB ’72) and Columbia University (MD ’81), he trained at Massachusetts General Hospital and at Children’s Hospital, Boston and was on staff at Children’s Hospital and Harvard… Read More »

Joyce E. Myers, MD

Vice President, Clinical Development

Dr. Myers is board certified in Diagnostic Radiology and Psychiatry with 30 years of both clinical and research experience in academics and industry, primarily in psychiatry and neuropharmacology. She received her BA and MD at Temple University.  She completed residency training in diagnostic radiology and psychiatry. While at the Western Psychiatric Institute and Clinic she… Read More »

Dave Ramsdell

Chief Financial Officer, Alopexx Enterprises

As a seasoned finance and operational professional, Dave has worked extensively in multiple industries. He has held senior roles in computer software, life sciences, distribution, market research, and retail. Dave has worked with venture and private equity backed companies, has raised multiple rounds of debt and equity financing, and has completed three IPO’s in his… Read More »